KoreaTechToday - Korea's Leading Tech and Startup Media Platform
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Lists
KoreaTechToday - Korea's Leading Tech and Startup Media Platform
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Lists
KoreaTechToday - Korea's Leading Tech and Startup Media Platform
No Result
View All Result
Home Biotech

LegoChem Biosciences Signs 496.3 Bln Won Licensing Deal with UK Iksuda

James Jung by James Jung
PUBLISHED: April 15, 2020 UPDATED: April 18, 2020
in Biotech, Iksuda Therapeutics, LegoChem Biosciences, Medical industry, South Korea
0
LegoChem Biosciences Inc. signed a 496.3 billion won agreement on licensing out its antibody-drug conjugate tech to UK-based Iksuda Therapeutics.
LegoChem Biosciences Inc. signed a 496.3 billion won agreement on licensing out its antibody-drug conjugate tech to UK-based Iksuda Therapeutics.

LegoChem Biosciences Inc. signed a 496.3 billion won agreement on licensing out its antibody-drug conjugate tech to UK-based Iksuda Therapeutics.

LegoChem Biosciences Inc. announced it signed a 496.3 billion won ($405 million) worth agreement on licensing out its antibody-drug conjugate (ADC) technology to Iksuda Therapeutics, a U.K.-based biotech company.

The South Korean biotech company licensed out its ADC linker/toxin technology named ConjuAll to Iskuda. The deal allows the British firm to exclusive rights to develop and commercialize three ADC-based cancer therapies internationally.

ADC links specific antibodies to antigens present on tumor cells using anticancer chemical drugs through a linker. LegoChem’s ConjuAll is an ADC-based technology that uses proprietary linker chemistry mixed with site-specific enzymatic conjugation.

Iksuda Therapeutics was founded in 2012 by renowned ADC experts.

Meanwhile, LegoChem could still license out its ConjuAll platform to other companies past the three arranged target therapies.

Licensing Agreement

LegoChem also signed a similar license agreement with Japan-based Takeda Pharmaceutical for ConjuAll last year. It received 8.9 billion won ($7.25 million) in upfront and near-term milestone payments. LegoChem is also eligible to receive development, regulatory and commercial milestone payments of up to 496 billion won ($404 million).

Under the agreement, LegoChem would receive 496.3 billion won ($405 million) upfront and milestone payments. The company would also receive the right to additional royalties on sales of related products in the future.

Based on predetermined ratios, LegoChem is eligible to receive a part of Iksuda’s out-licensing profit if Iksuda licenses out ConjuAll during its drug development process to a third party.

LegoChem CEO Kim Yong-zu said that Iksuda’s world-leading competence in developing ADC could send their technology to the clinical trial stage quicker than any company.

Iksuda CEO and co-founder Dr. David Simpson said that the company would take advantage of LegoChem’s excellent linker and next-generation PBD toxin to enter the clinical stage as fast as possible.

LegoChem reported a 16 billion won ($13 million) revenue last year. The company has signed six licensing agreements, including Iksuda’s deal, with a combined value of 1.7 trillion won ($1.39 billion).

Tags: 496.3 billion wonADCbiotechcancer treatmentclinical stageIksudaLegoChemlicensing dealSouth Korea news

Related Posts

Chazm Operator Wins Scale-up TIPS Selection to Expand Automotive Finance AI
LegoChem Biosciences Inc. signed a 496.3 billion won agreement on licensing out its antibody-drug conjugate tech to UK-based Iksuda Therapeutics.
AI

Chazm Operator Wins Scale-up TIPS Selection to Expand Automotive Finance AI

November 4, 2026
The Strategic Investment Trap: What Korean Startup Founders Should Consider Before Taking Corporate VC
LegoChem Biosciences Inc. signed a 496.3 billion won agreement on licensing out its antibody-drug conjugate tech to UK-based Iksuda Therapeutics.
AI

The Strategic Investment Trap: What Korean Startup Founders Should Consider Before Taking Corporate VC

November 1, 2026
India and South Korea Could Build a New Startup Corridor Around Manufacturing and Technology
LegoChem Biosciences Inc. signed a 496.3 billion won agreement on licensing out its antibody-drug conjugate tech to UK-based Iksuda Therapeutics.
South Korea

India and South Korea Could Build a New Startup Corridor Around Manufacturing and Technology

November 1, 2026
Why South Korea Could Become a Strategic Growth Partner for Southeast Asian Startups
LegoChem Biosciences Inc. signed a 496.3 billion won agreement on licensing out its antibody-drug conjugate tech to UK-based Iksuda Therapeutics.
South Korea

Why South Korea Could Become a Strategic Growth Partner for Southeast Asian Startups

November 1, 2026
From Lab Results to Licensing Deals: What Korean Biotech Startups Must Prove to Raise Capital
LegoChem Biosciences Inc. signed a 496.3 billion won agreement on licensing out its antibody-drug conjugate tech to UK-based Iksuda Therapeutics.
Biotech

From Lab Results to Licensing Deals: What Korean Biotech Startups Must Prove to Raise Capital

November 1, 2026
Korean Investors Need a Strategic Approach to Southeast Asia, Not Just More Capital
LegoChem Biosciences Inc. signed a 496.3 billion won agreement on licensing out its antibody-drug conjugate tech to UK-based Iksuda Therapeutics.
AI

Korean Investors Need a Strategic Approach to Southeast Asia, Not Just More Capital

November 1, 2026
No Result
View All Result

Most Popular

  • Naver Pay Reaches 30.68 Million Users, Expands Global and Local Payment Services

    0 shares
    Share 0 Tweet 0
  • Why South Korea’s Hyperconnected Economy Needs a More Integrated Cybersecurity Strategy

    0 shares
    Share 0 Tweet 0
  • Kakao in Talks to Sell Daum, With AI Startup Upstage as Top Contender

    0 shares
    Share 0 Tweet 0
  • LG Uplus Introduces OpenAI-Powered Agentic Callbot for Customer Phone Support

    0 shares
    Share 0 Tweet 0
  • Samsung and SK Hynix Face New U.S. Licensing Rules for Chinese Chip Plants

    0 shares
    Share 0 Tweet 0
  • Kakao Mobility Faces $10.5 Million Fine for Limiting Competitors’ Access to Taxi Platform

    0 shares
    Share 0 Tweet 0

PRODUCTS

[ads_amazon]

TOPICS

  • Naver
  • Kakao
  • Nexon
  • Netmarble
  • NCsoft
  • Samsung
  • Hyundai

FREE NEWSLETTER

[mc4wp_form id="4726"]

FOLLOW US

  • About Us
  • Cookie policy
  • home
  • homepage
  • mainhome
  • Our Services
  • Privacy Policy
  • Terms of Use

Copyright © 2024 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : [email protected] |

No Result
View All Result
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Lists

Copyright © 2024 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : [email protected] |